Intra-Arterial Gemcitabine Extends PFS in Locally Advanced Pancreatic Cancer
Intra-arterial administration of gemcitabine conferred a median PFS benefit of 8 months when compared with standard of care for patients with locally advanced pancreatic cancer, according to results of the phase 3 TiGeR-PaC study.